Jason Cohen, Editor

About the Author Jason Cohen, Editor


Omeros Corporation (OMER) Wows Investors with Strong Revenue Growth, But Elemer Piros Stays on the Sidelines

Cantor’s Elemer Piros waits for pass-through reimbursement to be address, before joining the ‘Omeros party’.

Read more

SAGE Therapeutics Inc (SAGE) Attains 52-Week High on Encouraging Clinical Results; Needham Cheers

Brexanolone poised to become first approved therapy for PPD, says Needham’s Danielle Brill.

Read more

Wall Street Is All Mixed Up About Teva Pharmaceutical; Jami Rubin Cuts Price Target

The market has divided itself into two camps. The bulls argue that the worst is …

Read more

Valeant Pharmaceuticals Intl Inc’s (VRX) Situation Remains Dire: Irina Rivkind Koffler

Is Valeant on track to overcome financial troubles? Mizuho’s Irina Rivkind Koffler remains unconvinced.

Read more

ACADIA Pharmaceuticals Inc.’s (ACAD) Phase II Study in Alzheimer’s Disease Psychosis Faces Criticism; Top Analyst Weighs In

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) tumbled nearly 9% in Monday’s trading session, after the …

Read more

TherapeuticsMD Inc (TXMD) Shares Fire Up to the Roof Following Positive FDA Resolution; William Tanner Cheers

TX-004 is on the path to FDA approval; Cantor’s William Tanner Sees 450% Upside.

Read more

MannKind Corporation (MNKD) Shares Slide as Maxim Heads to Sidelines

MannKind’s capital raise is not enough, says Jason Kolbert.

Read more

Biogen Inc (BIIB) Shares Slump as Spinraza US Sales Disappoint, But This Top Analyst Upbeat

Eric Schmidt views BIIB shares as undervalued based upon a stable MS franchise and Spinraza’s potential.

Read more

Ladenburg Sees 35% Upside for Transenterix Inc (TRXC), RBC Gets More Cautious on Valeant Pharmaceuticals Intl Inc (VRX)

Healthcare analysts take different approaches to valuing Transenterix and Valeant.

Read more

Cantor Boosts Price Target for Ignyta Inc (RXDX) on Back of Positive Clinical Data

ROS1-Positive interim data raises Mara Goldstein’s conviction.

Read more